Multiple Myeloma in African Americans Multiple Myeloma in African Americans: Understanding Differences in Incidence and Treatment

Treatment of Elderly Patients With Multiple Myeloma In this segment, Sundar Jagannath, MD; Shaji Kumar, MD; Sagar Lonial, MD; Jeffrey A. Zonder, MD; and James R. Berenson, MD, comment on treatment approaches in older patients with multiple myeloma.

What is Myeloma? | Cancer Research UK 2021 Find out about what myeloma is, how it starts, symptoms, and how your specialist plans the best treatment for you. 00:02 What is Myeloma? 00:33 Types of white blood cells 00:46 What do plasma cells do? 00:54 How myeloma starts 1:20 How myeloma causes symptoms 2:02 Why […]

Plasma Cell Disorders/Dyscrasias – Multiple Myeloma Pathology Review Plasma cell dyscrasias are a monoclonal proliferation of plasma cells that produce a clonal immunoglobulin protein (i.e., monoclonal gammopathies or paraproteinemias). They are derived from malignant B lymphocytes. Common plasma cell dyscrasias include multiple myeloma and Waldenström’s macroglobulinemia. Plasma cell disorders are a group of hematological malignancies […]

Dr. Lesokhin Discusses Exciting Advances in Multiple Myeloma Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses some of the exciting advancements currently happening in the field of multiple myeloma. According to Lesokhin, a lot of the excitement is around chimeric antigen receptor (CAR) T-cells, though […]

Expert Session – 11.10.2021 – Newly Diagnosed Multiple Myeloma (NDMM) During this FREE 2-hour Expert Session on newly diagnosed multiple myeloma, our faculty will provide myeloma patients—and their families and caregivers—with a clear understanding of multiple myeloma, including how it is diagnosed and treated and will take questions during 2 dedicated Q&A sessions.

MGUS and Smoldering Myeloma | Memorial Sloan Kettering Ola Landgren, Chief of Memorial Sloan Kettering’s Myeloma Service, explains disorders that predispose a person to myeloma and how they are treated. Learn about MSK: https://www.mskcc.org CONNECT WITH MSK Facebook: http://facebook.com/sloankettering Twitter: http://twitter.com/sloan_kettering Instagram: http://instagram.com/sloankettering Request an appointment at MSK by calling 800-525-2225 or online at: https://www.mskcc.org/appointments/request-appointment

What is Multiple Myeloma and how is treated? – Dr. Satish Kumar Multiple myeloma is also a cancer of the bone marrow. Myeloma starts in the bone marrow from a cell called as plasma cell. It is a cancer of the plasma cell. In Multiple myeloma, which is basically a cancer of the elderly, the […]

Once Weekly Selinexor, Carfilzomib, and Dexamethasone (XKd) in Heavily Pretreated Multiple Myeloma Background of the Study: Exportin 1 (XPO1) mediates the nuclear export and functional inactivation of tumor suppressor proteins (TSPs), is associated with poor prognosis in MM, and contributes to proteasome inhibitor (PI) and immunomodulatory drug (IMiD) resistance. Selinexor (SEL) is a novel, oral, […]

CAR T-Cell Therapy for Multiple Myeloma Keith Stewart, MB, ChB; Saad Z. Usmani, MD; Thomas G. Martin, MD; Sagar Lonial, MD; Ivan M. Borrello, MD; and Gareth Morgan, MD, PhD, highlight trials that are reviewing the potential use of chimeric antigen receptor T-cell therapy that targets the protein, B-cell maturation antigen in multiple myeloma.